Tenaya Therapeutics Statistics
Share Statistics
Tenaya Therapeutics has 79.22M shares outstanding. The number of shares has increased by 0.9% in one year.
| Shares Outstanding | 79.22M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.42% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 65.64M |
| Failed to Deliver (FTD) Shares | 426 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 16.69M, so 21.07% of the outstanding shares have been sold short.
| Short Interest | 16.69M |
| Short % of Shares Out | 21.07% |
| Short % of Float | 25.43% |
| Short Ratio (days to cover) | 3.42 |
Valuation Ratios
The PE ratio is -1.93 and the forward PE ratio is -1.77.
| PE Ratio | -1.93 |
| Forward PE | -1.77 |
| PS Ratio | 0 |
| Forward PS | 3.5 |
| PB Ratio | 1.71 |
| P/FCF Ratio | -2.31 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tenaya Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.91, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.91 |
| Quick Ratio | 4.91 |
| Debt / Equity | 0.09 |
| Total Debt / Capitalization | 8.18 |
| Cash Flow / Debt | -8.22 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.89% and return on capital (ROIC) is -86.4%.
| Return on Equity (ROE) | -0.89% |
| Return on Assets (ROA) | -0.73% |
| Return on Capital (ROIC) | -86.4% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -886.31K |
| Employee Count | 140 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -50.85% in the last 52 weeks. The beta is 2.35, so Tenaya Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.35 |
| 52-Week Price Change | -50.85% |
| 50-Day Moving Average | 2.29 |
| 200-Day Moving Average | 3.01 |
| Relative Strength Index (RSI) | 37.1 |
| Average Volume (20 Days) | 5.02M |
Income Statement
| Revenue | n/a |
| Gross Profit | -8.69M |
| Operating Income | -131.19M |
| Net Income | -124.08M |
| EBITDA | -122.51M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.68 |
Balance Sheet
The company has 45.68M in cash and 12.42M in debt, giving a net cash position of 33.26M.
| Cash & Cash Equivalents | 45.68M |
| Total Debt | 12.42M |
| Net Cash | 33.26M |
| Retained Earnings | -403.28M |
| Total Assets | 140.58M |
| Working Capital | 69.15M |
Cash Flow
In the last 12 months, operating cash flow was -102.07M and capital expenditures -1.24M, giving a free cash flow of -103.31M.
| Operating Cash Flow | -102.07M |
| Capital Expenditures | -1.24M |
| Free Cash Flow | -103.31M |
| FCF Per Share | -1.4 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TNYA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -116.67% |
| FCF Yield | -90.56% |
Analyst Forecast
The average price target for TNYA is $18, which is 1150% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 1150% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -4.49 |
| Piotroski F-Score | 2 |